LAUREN LUTZ: Open Payments
NPI 1417407743 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$76,129 in 279 payments from 19 companies in 2025. Trend: 2023 $107,839 · 2024 $93,992 · 2025 $76,129
Honoraria: $30,313Speaker / faculty: $27,775Travel & lodging: $7,312Consulting: $5,849Food & beverage: $4,671Education: $209
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 69 | $34,878 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $14,924 |
| Alkermes, Inc. | 39 | $11,057 |
| E.R. Squibb & Sons, L.L.C. | 31 | $7,831 |
| Vanda Pharmaceuticals Inc. | 30 | $6,171 |
| Neurocrine BioSciences, Inc. | 20 | $239 |
| Teva Pharmaceuticals USA, Inc. | 8 | $238 |
| Supernus Pharmaceuticals, Inc. | 16 | $197 |
| Otsuka America Pharmaceutical, Inc. | 16 | $188 |
| Lundbeck LLC | 4 | $76 |
Products named: Auvelity, CAPLYTA, LYBALVI, COBENFY, FANAPT, INGREZZA, Qelbree, ARISTADA.
Industry payments across IN — which companies pay providers there.
